BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marinelli O, Annibali D, Aguzzi C, Tuyaerts S, Amant F, Morelli MB, Santoni G, Amantini C, Maggi F, Nabissi M. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. Front Oncol 2019;9:1073. [PMID: 31681606 DOI: 10.3389/fonc.2019.01073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 James NE, Miller K, LaFranzo N, Lips E, Woodman M, Ou J, Ribeiro JR. Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer. Front Oncol 2021;11:622182. [PMID: 33747935 DOI: 10.3389/fonc.2021.622182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci 2021;22:6532. [PMID: 34207103 DOI: 10.3390/ijms22126532] [Reference Citation Analysis]
3 AlHilli MM, Bae-Jump V. Diet and gut microbiome interactions in gynecologic cancer. Gynecol Oncol 2020;159:299-308. [PMID: 32933758 DOI: 10.1016/j.ygyno.2020.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chew M, Wong YP, Karim N, Mustangin M, Alfian N, Tan GC. Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. Diagnostics (Basel) 2020;10:E394. [PMID: 32545177 DOI: 10.3390/diagnostics10060394] [Reference Citation Analysis]
5 Xu D, Dong P, Xiong Y, Chen R, Konno Y, Ihira K, Yue J, Watari H. PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3. Front Cell Dev Biol 2020;8:598205. [PMID: 33363153 DOI: 10.3389/fcell.2020.598205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Pawłowska A, Kwiatkowska A, Suszczyk D, Chudzik A, Tarkowski R, Barczyński B, Kotarski J, Wertel I. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. Int J Mol Sci 2021;22:11563. [PMID: 34768993 DOI: 10.3390/ijms222111563] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang Y, Liu Y, Guan Y, Li H, Liu Y, Zhang M, Cui P, Kong D, Chen X, Yin H. Integrated analysis of immune-related genes in endometrial carcinoma. Cancer Cell Int 2020;20:477. [PMID: 33024415 DOI: 10.1186/s12935-020-01572-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Reference Citation Analysis]
9 Drakes ML, Czerlanis CM, Stiff PJ. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers (Basel) 2020;12:E3301. [PMID: 33182298 DOI: 10.3390/cancers12113301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Amarin JZ, Mansour R, Al-Ghnimat S, Al-Hussaini M. Differential Characteristics and Prognosis of PD-L1-Positive Endometrial Carcinomas: A Retrospective Chart Review. Life (Basel) 2021;11:1047. [PMID: 34685418 DOI: 10.3390/life11101047] [Reference Citation Analysis]
11 Marinelli O, Annibali D, Morelli MB, Zeppa L, Tuyaerts S, Aguzzi C, Amantini C, Maggi F, Ferretti B, Santoni G, Amant F, Nabissi M. Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. Front Oncol 2020;10:538064. [PMID: 33194598 DOI: 10.3389/fonc.2020.538064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pradip, Jennifer A, Nandini D. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime. Int J Mol Sci 2021;22:9121. [PMID: 34502029 DOI: 10.3390/ijms22179121] [Reference Citation Analysis]
13 da Silva MC, Medeiros FS, da Silva NCH, Paiva LA, Gomes FODS, Costa E Silva M, Gomes TT, Peixoto CA, Rygaard MCV, Menezes MLB, Welkovic S, Donadi EA, Lucena-Silva N. Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (PDCD1) rs36084323 A Allele in a Dominant Model. Front Cell Infect Microbiol 2021;11:587932. [PMID: 34290992 DOI: 10.3389/fcimb.2021.587932] [Reference Citation Analysis]
14 Sepe P, Mennitto A, Corti F, Procopio G. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. Immunotargets Ther 2020;9:273-88. [PMID: 33224904 DOI: 10.2147/ITT.S240889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]